Pediatric telehealth matches in-person visits in effectiveness

Visiting the pediatrician without a fussy child can be blessing for many parents. But are remote sessions with a physician as effective as in-person visits? A recent study focused on TytoCare, a handheld mobile telehealth device, found remote visits are equivalent to in-office appointments.

Conducted by researchers at the Schneider Children’s Medical Center in Israel and New York's Sackler School of Medicine, the study compared the effectiveness of TytoCare’s platform with in-person visits. TytoCare includes exams on the ears, throat, lungs, skin and heart where physicians can conduct through a live video feed.

The study included 137 children, ages 2 to 18, looking for emergency department care. Patients were examined with conventional examination tools in a doctor’s office and again with physicians collecting exam data taken with TytoCare. Results showed that the telehealth platform achieved good to excellent reviews for all exams and remained on par for effectiveness and quality with in-person visits.

"The results are clear—examination findings achieved with TytoCare are on par with those reached by conventional examination tools," said Yehezkel Waisman, researcher on the study. "Beyond that, the quality of the readings as well as the overall user experience received positive ratings from physicians, a great testament to the solution's promise to provide accurate and confident diagnoses via telehealth technology."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.